Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-3.74%
+5.10%
+2.59%
+2.13%
-3.07%
ABBV
AbbVie
$198.47
Chart
209.17
191.83
175.58
166.42
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-3.74%
+5.10%
+2.59%
+2.13%
-3.07%
ABBV
AbbVie
$198.47
Chart
209.17
191.83
175.58
166.42
ABBV Latest Headlines
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis. The United States Food and Drug Administration on Tuesday approved ) Rinvoq (upadacitinib) 15 mg once daily for .GCA is an inflammation of blood vessels called arteries in and .Earlier in April the European Commission approved Rinvoq for giant cell arteritis .Rinvoq is the first and only oral JAK inhibitor approved in the EU Iceland Liechtenstein and Norway for adult patients with GCA.The approvals are suppor
Tue Apr 29, 2025
Stock Of The Day: AbbVies Rally Looks Stretched — Could A Reversal Be Next?. ) is trading higher Tuesday. The stock has been in an uptrend. In the past week it has gained more than 12%.But now it is overbought. This could draw sellers into the market and they could pressure AbbVie lower. Benzinga’.s team of technical analysts has made it the Stock of the Day.Overbought refers to the momentum of a stock. Most of the time it will stay in its normal or average trading range. If it is aggressiv
Tue Apr 29, 2025
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It. Recently Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Tue Apr 29, 2025
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst. On Friday ) reported an adjusted EPS of $2.46 up 6.5% year over year and beating the.The pharmaceutical giant reported sales of $13.34 billion up 8.4% on a reported basis (9.8% on an operational basis) beating the .It reported adjusted earnings per share of $2.46 beating the street view of $2.38.BMO Capital Markets writes that every quarter seems to tell the same story. Analysts think they’.ve accurately factored
Mon Apr 28, 2025
Should Investors Be Worried About Dividend King AbbVie?. Nearly everything looked great with AbbVies (NYSE: ABBV) first-quarter results. The big drugmakers revenue jumped 8.4% year over year thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq. AbbVie beat Wall Streets top- and bottom-line estimates
Mon Apr 28, 2025
AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts.
Mon Apr 28, 2025
AbbVies First Quarter Beat And Raise Leaves Room For More.
Fri Apr 25, 2025
AbbVie: Q1 Earnings Reinforce Positive Momentum.
Fri Apr 25, 2025
AbbVie Beats on Q1 Earnings & Sales Raises 25 EPS View. ABBVs first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Fri Apr 25, 2025
AbbVie Q1 Earnings Review: Typically Strong Performance Aesthetics Aside.
Fri Apr 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Login to display AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
